BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
BioXcel Therapeutics files for Chapter 11 bankruptcy and agrees to sell its assets to Teva Pharmaceutical for up to $125M.
BioXcel Therapeutics
NASDAQ: BTAI $0.07 USD
Clinical-stage biopharmaceutical company using AI to identify and develop novel therapies in neuroscience and immuno-oncology. Filed for bankruptcy in August 2026 and agreed to sell assets to Teva Pharmaceutical for up to $125M.
Company Info
Sector:Neuroscience / Immuno-Oncology
Headquarters:New Haven, Connecticut, USA
Founded:2017
Website:www.bioxceltherapeutics.com/
Upcoming Milestones & Key Dates
2026
M&A
Asset sale to Teva for up to $125M